Positive results from phase IIIb BE RADIANT study of bimekizumab, vs. secukinumab in patients with moderate-to-severe plaque psoriasis

This is first head-to-head study (n=743) comparing anti-IL-17 treatments. It met its primary endpoint at week 16, demonstrating superiority of bimekizumab over secukinumab for complete skin clearance, as measured by 100% improvement in Psoriasis Area and Severity Index (PASI 100)


Biospace Inc.